Fenwick Represents Caldera Therapeutics in $112.5M Funding

Fenwick represented Caldera Therapeutics, a clinical-stage biotechnology company developing the first-in-class bispecific antibody CLD-423 for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases, in its $112.5 million funding. The $75 million Series A round included participation from Atlas Venture, LAV, and venBio. The $37.5 million Series A-1 round was led by Omega Funds, with participation from Wellington Management and Janus Henderson Investors Proceeds.

Caldera Therapeutics will use the funds to support ongoing clinical development of CLD-423, a bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways. More information can be obtained here.

The Fenwick transaction team was led by corporate partners Effie Toshav and Ryan McRobert and included associates Olga Terets and Kale Olmstead.